RCUS Arcus Biosciences, Inc.
FY2025 10-K
Arcus Biosciences, Inc. (RCUS) filed its fiscal year 2025 10-K annual report with the SEC on Feb 25, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: Development and commercialization of investigational pharmaceutical products in immuno-oncology
- • No new products or segments introduced; increased emphasis on regulatory, pricing, and healthcare reform risks in U.S. markets
Management Discussion & Analysis
- • No product sales revenue; all revenue from license, collaboration, and development services agreements
- • License and development services revenue recognized based on percentage completion of R&D obligations
Risk Factors
- • Regulatory risk from Gilead collaboration amendment causing revenue catch-up of $143M in 2025, impacting timing and recognition of license income
- • Macroeconomic exposure to collaboration funding variability, e.g., Taiho option revenue dropped from $15M in 2024 to $7M in 2025
Financial SummaryXBRL
Revenue
$33M
Net Income
-$353M
Operating Margin
-1169.7%
Net Margin
-1069.7%
ROE
-55.9%
Total Assets
$1.1B
EPS (Diluted)
$-3.29
Operating Cash Flow
-$482M
Source: XBRL data from Arcus Biosciences, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Arcus Biosciences, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.